{
 "name": "博研醫藥",
 "slug": "tw-7891",
 "aliases": [
  "博研醫藥開發股份有限公司",
  "BoYen",
  "7891"
 ],
 "ticker": "7891",
 "industry": "生技醫療業",
 "website": "https://www.boyentherapeutics.com",
 "summary": "博研醫藥（7891）是興櫃的生技醫療類股公司，2010 年成立，2026 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "博研醫藥開發股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "BoYen",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2026-01-14",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2010-06-24",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "吳逸之",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "吳逸之",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 194300000,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "勤業眾信聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "https://www.boyentherapeutics.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：BY-101（clofarabine／氯法拉濱；試驗製劑SPT8278）",
   "value": "急性骨髓性白血病鞏固化療（合併cytarabine）｜第二期b臨床試驗進行中｜台灣",
   "unit": "",
   "as_of": "2026-01-12",
   "source": "https://mopsov.twse.com.tw/nas/STR/789120260112M001.pdf",
   "note": "2026-01-12法說簡報第18頁列出IIb期試驗及台灣已收案／開始收案醫院。NCT編號本次以Boyen、BY-101檢索查無。"
  },
  {
   "claim": "管線：BY-102（BYT-1007）",
   "value": "多發性硬化症｜臨床試驗準備中，GLP毒性及基因毒試驗已完成｜澳大利亞（規劃）",
   "unit": "",
   "as_of": "2026-01-12",
   "source": "https://mopsov.twse.com.tw/nas/STR/789120260112M001.pdf",
   "note": "第9、16頁對應BY-102=BYT-1007及MS；第19頁標臨床試驗準備中、試驗國家澳大利亞。不同適應症別未互相推定臨床核准。"
  },
  {
   "claim": "管線：BYT-1007（BY-103開發項目）",
   "value": "急性骨髓性白血病｜澳洲HREC已核准進行第一期臨床試驗｜澳洲",
   "unit": "",
   "as_of": "2026-09-11",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "查詢7891、115年度、全年度、序號1。發言日期2026-09-11 16:50:55；主旨：代子公司Boyen Therapeutics Australia Pty Ltd公告BYT-1007獲得澳洲人體研究倫理委員會(HREC)核准進行臨床一期試驗。2026-06-19原公告BY-103後更正為BYT-1007；法說第9、16頁對應BY-103=BYT-1007。只記HREC核准，不當作已收案。"
  }
 ],
 "provided_by": "public_sources",
 "verified_at": "2026-10-22",
 "url": "https://drugnews.com.tw/companies/tw-7891.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}